your badges 52W Range $74–$122 38% of range Analyst Rating BUY 23 analysts Price Target $139 +50% upside P/E -29.7 ROE -450.9% Net Profit Margin -85.6%

RYTM Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range

03
Price $92.45
Market Cap (MRQ) $6.36B
P/E (TTM) -29.7
EPS (TTM) $-3.11
Revenue (TTM) $240M
ROE (TTM) -450.9%
Debt/Equity (MRQ) 1.0
52W Range $75–$122

RYTM Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view

04
range
bars

Bar granularity adapts to the selected period — hover the chart to see open/high/low/close for a bar.

About Rhythm Pharmaceuticals, Inc. - Common Stock Company overview from Wikipedia

05 · wikidata
sectorHealthcare industryBiotechnology employees414 countryUS

10-Year Performance Revenue, net income, margins and EPS trends

06
Revenue$190M
2016-12-31 → 2025-12-31
EPS$-3.11
2019-12-31 → 2025-12-31
Free Cash Flow$-117M
2017-12-31 → 2025-12-31
Net margin-85.6%
2021-12-31 → 2025-12-31
Valuation & Ratios 07–12

Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?

Metric 5Y trend RYTM 5Y avg Peer Median Verdict
P/E (TTM) -29.75Y avg ≈-15.4 ≈-15.4 · ·
P/S (TTM) 26.55Y avg ≈65.8 ≈65.8 25.1 Pricier
P/B (MRQ) 61.85Y avg ≈47.3 ≈47.3 18.6 Overvalued
EV / EBITDA -31.0 · · ·
Price / FCF -53.35Y avg ≈-23.7 ≈-23.7 · ·
Price / Cash Flow -53.75Y avg ≈-25.2 ≈-25.2 · ·
EV / Revenue (TTM) 25.6 · · ·
EV / FCF -50.9 · · ·
Price / Tangible Book (MRQ) 64.95Y avg ≈60.7 ≈60.7 · ·

Peer median is calculated on a standardized basis per metric and may not always match the TTM/MRQ basis shown for this stock.

value · ≈ 5Y avg · industry median · verdict relative to median

Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date

14
Avg Surprise -0.46%
Next Report Nov 02, 2026
PeriodReportEPS ActualEPS EstSurprise
June 30, 2026 Aug 3, 2026 $-0.73 $-0.84 12.8%
March 31, 2026 $-0.83 $-0.87 4.6%
Dec. 31, 2025 $-0.73 $-0.84 12.9%
Sept. 30, 2025 $-0.82 $-0.74 -11.1%
June 30, 2025 $-0.75 $-0.69 -8.8%
March 31, 2025 $-0.81 $-0.72 -13.2%

Full Fundamentals All metrics by year — income statement, balance sheet, cash flow

15
Income Statement 17
Metric Trend 2025202420232022202120202019201820172016
Revenue $190M$130M$77M$24M$3M$0$0$0$0$0
Cost of Revenue $19M$13M$9M$2M$599.0K·····
R&D Expense $167M$238M$135M$109M$104M$90M$109M$50M$23M$20M
SG&A Expense $195M$144M$118M$92M$68M$46M$37M$28M$10M$6M
Operating Expenses $382M$396M$262M$203M$173M$137M$146M$78M$32M$26M
Operating Income $-192M$-266M$-184M$-179M$-170M$-137M$-146M$-78M$-32M$-26M
Interest Expense ··$14M$5M······
Interest Income ····$447.0K$3M$5M$4M$566.0K$33.0K
Other Non-op $1M$2M$190.0K$-790.0K$100M$3M$5M$4M$-1M$33.0K
Pretax Income $-196M$-260M$-184M$-181M$-70M·····
Income Tax $497.0K$346.0K$564.0K·······
Net Income $-197M$-261M$-185M$-181M$-70M$-134M$-141M$-74M$-34M$-26M
EPS (Basic) $-3.11$-4.34$-3.20$-3.47$-1.40$-3.04$-3.86···
EPS (Diluted) $-3.11$-4.34$-3.20$-3.47$-1.40$-3.04$-3.86···
Shares (Basic) 64,984,36160,995,20457,673,12852,120,70149,600,29444,127,22036,422,450···
Shares (Diluted) 64,984,36160,995,20457,673,12852,120,70149,600,29444,127,22036,422,450···
EBITDA $-192M$-265M$-183M$-178M$-169M$-136M$-145M$-78M$-32M·
Balance Sheet 27
Metric Trend 2025202420232022202120202019201820172016
Cash & Equivalents $54M$89M$60M$128M$59M$101M$62M$50M$34M$7M
Short-term Investments $335M$231M$216M$206M$236M$72M$230M·$114M$4M
Receivables $26M$19M$15M$6M$1M·····
Inventory $26M$19M$9M$3M$111.0K·····
Prepaid Expense $26M$16M$9M$12M$12M$9M$10M$7M$3M$638.0K
Other Current Assets $10M$9M$7M$7M$4M$3M$4M$1M$1M$216.0K
Current Assets $467M$374M$308M$354M$308M$182M$302M$259M$151M$11M
PP&E (Net) $1M$632.0K$1M$2M$3M$3M$4M$1M$840.0K$930.0K
PP&E (Gross) $6M$5M$5M$5M$5M$5M$4M$2M$1M$1M
Accum. Depreciation $5M$5M$4M$3M$2M$1M$752.0K$809.0K$367.0K$144.0K
Intangibles $5M$6M$7M$8M$5M·····
Other Non-current Assets $3M$7M$15M$17M······
Total Assets $480M$392M$333M$382M$330M$187M$309M$260M$152M$12M
Accounts Payable $14M$12M$5M$5M$6M$5M$10M$8M$2M$2M
Accrued Liabilities $84M$63M$48M$33M$30M$13M$14M$6M$4M$3M
Current Liabilities $106M$116M$55M$40M$43M$18M$24M$14M$7M$5M
Capital Leases $3M$4M$490.0K$1M$2M·····
Total Liabilities $210M$228M$163M$118M$45M$21M$28M$14M$7M$5M
Long-term Debt $108M$110M········
Total Debt $108M$110M········
Common Stock $67.0K$61.0K$59.0K$56.0K$50.0K$44.0K$44.0K$34.0K$27.0K$10.0K
Paid-in Capital $1.49B$1.18B$1.06B$974M$813M$626M$606M$431M$255M$44M
Retained Earnings $-1.35B$-1.16B$-895M$-710M$-529M$-459M$-325M$-185M$-110M$-77M
AOCI $-796.0K$-39.0K$134.0K$-92.0K$-1.0K$49.0K····
Stockholders' Equity $139M$22M$170M$264M$284M$167M$281M$246M$145M$-33M
Liabilities + Equity $480M$392M$333M$382M$330M$187M$309M$260M$152M$12M
Shares Outstanding 67,205,32162,390,65459,426,55956,612,42950,283,57444,235,90343,996,75334,410,72527,284,14010,196,292
Cash Flow 16
Metric Trend 2025202420232022202120202019201820172016
D&A $500.0K$700.0K$900.0K$896.0K$816.0K$690.0K$834.0K$442.0K$223.0K$144.0K
Stock-based Comp $67M$40M$33M$20M$21M$17M$12M$6M$2M$1M
Deferred Tax $0$0$0····$0$0$0
Amort. of Intangibles ··$855.0K$774.0K$342.0K·····
Other Non-cash $14M$106M$15M$-13M$-98M$-6M$5M$5M$2M·
Operating Cash Flow $-116M$-114M$-136M$-173M$-146M$-122M$-123M$-62M$-29M$-23M
CapEx $953.0K$0$47.0K$281.0K$434.0K$214.0K$3M$722.0K$133.0K$1M
Investing Cash Flow $-137M$-48M$-6M$28M$-62M$159M$-28M$-87M$-110M$-5M
Debt Issued $0$0$24M$72M······
Net Debt Issued $-20M$-13M$17M$72M······
Stock Issued $34M$39M$49M$131M$162M·$161M$163M$126M·
Net Stock Activity $34M$39M$49M$131M$162M·$161M$163M$126M·
Financing Cash Flow $218M$191M$74M$214M$166M$2M$163M$165M$167M·
Net Change in Cash $-35M$29M$-68M$68M$-42M$39M$13M$15M$28M$-28M
Free Cash Flow $-117M·$-136M$-174M$-146M$-122M$-126M$-63M$-30M·
Levered FCF ··$-150M·······
Profitability 7
Metric Trend 2025202420232022202120202019201820172016
Operating Margin -101.2%-204.0%-238.1%-757.9%-5391.9%·····
Net Margin -103.6%-200.3%-238.5%-766.2%-2207.1%·····
Pretax Margin -103.3%-200.0%-237.8%·······
EBITDA Margin -100.9%-203.5%-236.9%-754.1%-5366.0%·····
ROA -45.1%-71.9%-51.6%-50.9%-27.0%-54.1%-49.5%-36.0%-41.1%·
ROE -309.1%-1582.1%-100.6%-66.4%-23.0%-73.7%-65.4%-28.7%-60.2%·
ROIC -77.9%-202.1%-108.9%·······
Liquidity & Solvency 5
Metric Trend 2025202420232022202120202019201820172016
Current Ratio 4.43.25.68.97.110.112.419.022.4·
Quick Ratio 3.92.95.38.56.89.62.63.622.0·
Debt / Equity 0.85.1········
LT Debt / Equity 0.75.0········
Interest Coverage ··-13.3-34.4······
Efficiency 3
Metric Trend 2025202420232022202120202019201820172016
Asset Turnover 0.40.40.20.10.00.00.00.00.0·
Inventory Turnover 0.91.01.61.410.8·····
Receivables Turnover 8.57.87.36.56.2·····
Per Share 5
Metric Trend 2025202420232022202120202019201820172016
Book Value / Share $2.07$0.35$2.86$4.67$5.65$3.76$6.39$7.16$5.31·
Revenue / Share $2.92$2.13$1.34$0.45$0.06·····
Cash Flow / Share $-1.78$-1.87$-2.36$-3.33$-2.94·····
Cash / Share $0.81$1.43$1.01$2.26$1.18$2.28$1.42$1.44$1.25·
EPS (TTM) $-3.11$-4.34$-3.20$-3.47$-1.40$-3.04$-3.86···
Growth Rates 2
Metric Trend 2025202420232022202120202019201820172016
Revenue YoY 45.8%68.1%227.6%649.5%······
Revenue CAGR 3Y 100.2%245.5%········
Valuation (TTM) 14
Metric Trend 2025202420232022202120202019201820172016
Revenue TTM $190M$130M$77M$24M$3M$0$0$0$0·
Net Income TTM $-197M$-261M$-185M$-181M$-70M$-134M$-141M$-74M$-34M·
Market Cap $7.19B$3.49B$2.73B$1.65B$502M$1.32B$1.01B$925M$793M·
Enterprise Value $6.91B$3.28B········
P/E -34.4-12.9-14.4-8.4-7.1-9.8-5.9···
P/S 37.926.835.369.7159.1·····
P/B 51.7160.716.16.21.87.93.63.85.5·
P / Tangible Book 53.8224.516.86.41.87.9····
P / Cash Flow -62.2-30.7-20.1-9.5-3.4-10.8-8.2-14.9-26.9·
P / FCF -61.7·-20.1-9.5-3.4-10.8-8.0-14.7-26.8·
EV / EBITDA -36.1-12.4········
EV / FCF -59.3·········
EV / Revenue 36.425.2········
Earnings Yield -2.9%-7.8%-7.0%-11.9%-14.0%-10.2%-16.8%···

Most recent period on the left · null values shown as ·

Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years

16
Metric 2025-12-312024-12-312023-12-312022-12-312021-12-31
Revenue $190M $130M $77M $24M $3M
Operating Margin % -101.2% -204.0% -238.1% -757.9% -5391.9%
Net Income $-197M $-261M $-185M $-181M $-70M
Diluted EPS $-3.11 $-4.34 $-3.20 $-3.47 $-1.40

Institutional owners (13F) 320 filers · $8.9B total · As of Sept. 30, 2026

17

Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.

Holders 320
Value held $8.9B
New positions 59
Exited positions 38
Institutional activity — Q2 2026 vs prior quarter
New positions Exited positions Increased Decreased Net shares change
59 (-7 vs prior Q) 38 (-9 vs prior Q) 106 (+7 vs prior Q) 100 (+10 vs prior Q) +3.0M

Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.

Institution Value Shares % of tracked 13F Type
RA CAPITAL MANAGEMENT, L.P. $740,218,912 6,666,837 8.32% Shares
BlackRock, Inc. $683,600,828 6,156,902 7.69% Shares
VANGUARD GROUP INC $664,816,448 6,210,916 7.48% Shares
BAKER BROS. ADVISORS LP $622,265,747 5,604,483 7.00% Shares
PRIMECAP MANAGEMENT CO/CA/ $351,837,748 3,168,853 3.96% Shares
VANGUARD PORTFOLIO MANAGEMENT LLC $348,289,452 3,136,895 3.92% Shares
VANGUARD CAPITAL MANAGEMENT LLC $333,753,626 3,005,977 3.75% Shares
JPMORGAN CHASE & CO $292,178,898 2,652,746 3.29% Shares
PERCEPTIVE ADVISORS LLC $287,156,334 2,586,295 3.23% Shares
STATE STREET CORP $285,728,722 2,573,529 3.21% Shares
WESTFIELD CAPITAL MANAGEMENT CO LP $245,220,303 2,208,595 2.76% Shares
GOLDMAN SACHS GROUP INC $236,105,516 2,126,502 2.65% Shares
FEDERATED HERMES, INC. $198,268,047 1,785,716 2.23% Shares
Polar Capital Holdings Plc $184,713,061 1,663,632 2.08% Shares
GEODE CAPITAL MANAGEMENT, LLC $170,320,392 1,533,698 1.92% Shares
Capital Research Global Investors $170,131,602 1,532,303 1.91% Shares
CITADEL ADVISORS LLC $140,303,282 1,263,652 1.58% Shares
Checkpoint Capital L.P. $131,681,580 1,186,000 1.48% Shares
Siren, L.L.C. $126,160,613 1,136,275 1.42% Shares
MORGAN STANLEY $123,492,178 1,112,240 1.39% Shares
FMR LLC $113,899,059 1,025,840 1.28% Shares
Pictet Asset Management Holding SA $106,252,095 957,785 1.19% Shares
Woodline Partners LP $84,259,668 758,891 0.95% Shares
JANUS HENDERSON GROUP PLC $79,886,248 918,153 0.90% Shares
ALLIANCEBERNSTEIN L.P. $77,814,059 894,723 0.87% Shares
Clearbridge Investments, LLC $77,329,368 696,473 0.87% Shares
Rock Springs Capital Management LP $76,899,156 692,598 0.86% Shares
NORGES BANK $76,149,259 685,844 0.86% Shares
FRANKLIN RESOURCES INC $64,067,973 577,033 0.72% Shares
CHARLES SCHWAB INVESTMENT MANAGEMENT INC $61,370,500 552,738 0.69% Shares
Integral Health Asset Management, LLC $61,066,500 550,000 0.69% Shares
Invesco Ltd. $60,319,379 543,271 0.68% Shares
NORTHERN TRUST CORP $59,993,061 540,332 0.67% Shares
WELLINGTON MANAGEMENT GROUP LLP $54,265,580 488,747 0.61% Shares
VANGUARD FIDUCIARY TRUST CO $49,488,625 445,723 0.56% Shares
LOOMIS SAYLES & CO L P $48,198,345 434,102 0.54% Shares
Candriam S.C.A. $48,032,508 433,025 0.54% Shares
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC $47,089,907 541,450 0.53% Shares
Squarepoint Ops LLC $46,956,919 422,921 0.53% Shares
Point72 Asset Management, L.P. $45,989,736 414,210 0.52% Shares
Sofinnova Investments, Inc. $45,303,238 408,027 0.51% Shares
AMERIPRISE FINANCIAL INC $44,593,674 401,634 0.50% Shares
ADAGE CAPITAL PARTNERS GP, L.L.C. $44,078,910 397,000 0.50% Shares
Bank of New York Mellon Corp $43,750,776 394,044 0.49% Shares
BRAIDWELL LP $42,316,642 381,128 0.48% Shares
Artisan Partners Limited Partnership $39,395,220 354,816 0.44% Shares
BANK OF AMERICA CORP /DE/ $36,136,934 325,470 0.41% Shares
ORBIMED ADVISORS LLC $35,851,587 322,900 0.40% Shares
MILLENNIUM MANAGEMENT LLC $35,165,311 316,719 0.40% Shares
SILVERARC CAPITAL MANAGEMENT, LLC $34,581,515 311,461 0.39% Shares

Show all 320 institutional owners →

Activists & 5%+ owners 7 positions

18

Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.

Filer Filed Stake Status Purpose Filing
April 30, 2024 · Initial filing · SEC
Perceptive Advisors LLC, Perceptive Life Sciences Master Fund, Ltd., C2 Life Sciences LLC, Perceptive Discovery Fund LP, Joseph Edelman ×3 filings April 17, 2024 · Initial filing · SEC
New Enterprise Associates 13, L.P., NEA Partners 13, L.P., NEA 13 GP, LTD, Forest Baskett, Patrick J. Kerins, Scott D. Sandell ×2 filings March 29, 2023 · Initial filing Passive investment SEC
MPM BioVentures V, L.P., MPM Asset Management Investors BV5 LLC, MPM BioVentures V GP LLC, MPM BioVentures V LLC, Ansbert Gadicke, Luke Evnin, Todd Foley ×2 filings June 26, 2020 · Initial filing · SEC
Undisclosed reporting person, Undisclosed reporting person, Undisclosed reporting person, Undisclosed reporting person, Undisclosed reporting person Feb. 5, 2020 · Initial filing · SEC
Undisclosed reporting person, Undisclosed reporting person, Undisclosed reporting person, Undisclosed reporting person Feb. 12, 2019 · Initial filing Passive investment SEC
OrbiMed Advisors LLC, OrbiMed Capital GP V LLC ×5 filings Aug. 10, 2018 · Initial filing · SEC

Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.

Company insiders 37 insiders · 16 officers · 12 directors

19
Insider Role Last activity Shares owned Buys 12m Sells 12m Net 12m
David P Meeker President and CEO Sept. 14, 2026 M 239,258 0 5 $-5,133,559
Keith Michael Gottesdiener CEO & President March 9, 2020 M 558,250 0 0 $0
Hunter C Smith Chief Financial Officer Aug. 31, 2026 M 114,024 0 26 $-8,837,032
Manher Joshi Chief Medical Officer Aug. 17, 2026 A · 0 0 $0
Alastair Garfield Chief Scientific Officer Aug. 13, 2026 S 2,295 0 4 $-912,697
Joseph Shulman Chief Technical Officer Aug. 13, 2026 M 15,915 0 6 $-3,672,703
Jennifer Chien EVP, Head of North America Aug. 13, 2026 M 0 0 1 $-8,901,395
Yann Mazabraud EVP, Head of International Aug. 12, 2026 M 55,655 0 6 $-6,620,591
Christopher Paul German Corporate Controller & CAO May 15, 2026 M 0 0 2 $-930,921
Pamela J. Cramer Chief Human Resources Officer Feb. 11, 2026 A 29,376 0 4 $-2,987,366
William T. Roberts Chief Accounting Officer March 29, 2023 M 7,872 0 0 $0
Linda Shapiro Manning Chief Medical Officer Feb. 9, 2022 A · 0 0 $0
Murray Stewart Chief Medical Officer Feb. 11, 2021 A · 0 0 $0
Nithya Desikan Chief Commercial Officer Aug. 31, 2020 M 43,602 0 0 $0
Leonardus H.T. Van Der Ploeg Chief Scientific Officer May 31, 2019 M 42,339 0 0 $0
Fred T. Fiedorek Chief Medical Officer Feb. 14, 2018 A · 0 0 $0
Lynn A. Tetrault Director June 24, 2026 A 11,712 0 1 $-3,711,840
Stuart A Arbuckle Director June 24, 2026 A 11,712 0 0 $0
Christophe Jean Director June 24, 2026 A 11,712 0 0 $0
Jennifer L Good Director June 24, 2026 A 11,712 0 0 $0
David W J Mcgirr Director June 24, 2026 A 11,712 0 0 $0
Kimberly J Popovits Director April 1, 2026 A · 0 0 $0
Edward T. Mathers Director March 12, 2026 J 14,168 0 0 $0
Camille L Bedrosian Director June 24, 2025 A 7,000 0 0 $0
Todd Foley Director March 15, 2021 S 909,258 0 0 $0
Neil Exter Director June 6, 2018 A 0 0 0 $0
Hadley Harbor Master Investors (Cayman) L.P. 10% owner Oct. 10, 2017 C 545,256 0 0 $0
Ravi Viswanathan 10% owner Oct. 10, 2017 C 4,909,956 0 0 $0
Ipsen, S.A. 10% owner Oct. 10, 2017 C 833,099 0 0 $0
Forest Baskett 10% owner Oct. 10, 2017 C 4,909,956 0 0 $0
Patrick J. Kerins 10% owner Oct. 10, 2017 C 4,909,956 0 0 $0
David M Mott 10% owner Oct. 10, 2017 C 4,909,956 0 0 $0
James M Barrett 10% owner Oct. 10, 2017 C 4,909,956 0 0 $0
Peter J Barris 10% owner Oct. 10, 2017 C 4,909,956 0 0 $0
Pfizer Inc. 10% owner Oct. 10, 2017 C 1,427,639 0 0 $0
Simon Kelner · Feb. 11, 2021 A · 0 0 $0
Scott D. Sandell · Oct. 10, 2017 C 4,909,956 0 0 $0

Insiders from SEC Form 3/4/5 filings; net = open-market P/S only

ETF ownership Held by 35 ETFs

20

Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.

Fund Weight Units As of Source
MEDI · Harbor ETF Trust 4.02% 16,680 NS July 31, 2026 N-PORT
BBP · ETFis Series Trust I 1.55% 15,357 NS July 31, 2026 N-PORT
LABU · Direxion Shares ETF Trust 0.79% 39,370 NS July 31, 2026 N-PORT
DWAS · Invesco Exchange-Traded Fund Trust … 0.59% 25,494 SH Oct. 2, 2026 Daily
FNY · First Trust Exchange-Traded AlphaDE… 0.57% 33,067 NS July 31, 2026 N-PORT
IBB · iShares Trust 0.50% 507,659 SH Sept. 11, 2026 Daily
IBBQ · Invesco Exchange-Traded Fund Trust … 0.43% 4,873 SH Oct. 2, 2026 Daily
IWO · iShares Trust 0.37% 517,925 SH Sept. 11, 2026 Daily
VTWG · VANGUARD SCOTTSDALE FUNDS 0.36% 59,038 SH Aug. 19, 2026 Daily
PWS · Pacer Funds Trust 0.22% 538 NS July 31, 2026 N-PORT
BKSE · BNY Mellon ETF Trust 0.22% 1,927 NS July 31, 2026 N-PORT
VBK · VANGUARD INDEX FUNDS 0.21% 908,106 SH Aug. 19, 2026 Daily
BBSC · J.P. Morgan Exchange-Traded Fund Tr… 0.21% 14,383 NS July 31, 2026 N-PORT
FNX · First Trust Exchange-Traded AlphaDE… 0.20% 27,831 NS July 31, 2026 N-PORT
VTWO · VANGUARD SCOTTSDALE FUNDS 0.19% 317,548 SH Aug. 19, 2026 Daily
IWM · iShares Trust 0.18% 1,410,048 SH Sept. 11, 2026 Daily
ISCG · iShares Trust 0.18% 16,741 SH Sept. 11, 2026 Daily
RSSL · Global X Funds 0.18% 26,425 NS July 31, 2026 N-PORT
FAD · First Trust Exchange-Traded AlphaDE… 0.17% 9,930 NS July 31, 2026 N-PORT
VB · VANGUARD INDEX FUNDS 0.09% 1,571,929 SH Aug. 19, 2026 Daily
VHT · VANGUARD WORLD FUND 0.09% 164,403 SH Aug. 19, 2026 Daily
VXF · VANGUARD INDEX FUNDS 0.08% 715,506 SH Aug. 19, 2026 Daily
FHLC · FIDELITY COVINGTON TRUST 0.08% 25,957 NS July 31, 2026 N-PORT
WSML · iShares Trust 0.05% 3,457 SH Sept. 11, 2026 Daily
ESML · iShares Trust 0.05% 14,054 SH Sept. 11, 2026 Daily
PRFZ · Invesco Exchange-Traded Fund Trust 0.04% 12,237 SH Oct. 2, 2026 Daily
TILT · FlexShares Trust 0.01% 3,058 NS July 31, 2026 N-PORT
VTI · VANGUARD INDEX FUNDS 0.01% 2,177,236 SH Aug. 19, 2026 Daily
VTHR · VANGUARD SCOTTSDALE FUNDS 0.01% 4,502 SH Aug. 19, 2026 Daily
ESGV · VANGUARD WORLD FUND 0.01% 12,173 SH Aug. 19, 2026 Daily
ITOT · iShares Trust 0.01% 83,940 SH Sept. 11, 2026 Daily
IWV · iShares Trust 0.01% 14,197 SH Sept. 11, 2026 Daily
VT · VANGUARD INTERNATIONAL EQUITY INDEX… 0.00% 43,280 SH Aug. 19, 2026 Daily
ISCB · iShares Trust · 2,395 SH Sept. 11, 2026 Daily
SMLF · iShares Trust · 49,815 SH Sept. 11, 2026 Daily

RYTM Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside

21
rating · 23 analysts BUY
Median target $143.00 +54.7%
8 34.8% Strong Buy
12 52.2% Buy
3 13.0% Hold
0 0.0% Sell
0 0.0% Strong Sell

12-Month Price Target

17 analysts · 2026-09-29

Mean target $138.59 +49.9%

← Below all targets Current price $92.45
Low$105.00 Mean$138.59 High$160.00

Peer comparison (GICS sub-industry) Key metrics vs sector peers

22

FY basis, prices as of each company's last fiscal year-end close.

Ticker Market Cap P/E Rev YoY Net Margin ROE Gross Margin
RYTM $7.19B -34.4 45.8% -103.6% -309.1% ·
GRAL $3.45B -7.7 17.2% -277.5% -16.7% ·
IMVT $5.07B -9.0 229.2% · -73.7% ·
IOVA $1.12B -2.5 60.6% -148.4% -56.0% ·
CGON $3.35B -20.0 254.7% -3985.0% -22.6% ·
KOD $1.73B -6.5 · · -202.0% ·
ORKA $1.48B -3.3 · · -25.9% ·
TVTX $3.47B -131.8 110.5% -5.2% -34.6% ·
COGT $5.72B -16.4 · · -83.1% ·
PTCT $6.19B 9.8 114.5% 39.4% -331.5% ·

Latest News Recent headlines mentioning this company

23
Why Rhythm Pharmaceuticals Stock Triumphed on Tuesday Nasdaq · 5 months ago Is Rhythm Pharmaceuticals, Inc. (RYTM) A Good Stock To Buy Now? Yahoo Finance · 5 months, 1 week ago Rhythm Grabs A New Obesity Approval; How It Edged In Where Lilly, Novo 'Have Fallen Flat' Yahoo Finance · 6 months, 1 week ago

My Metrics Your personal watchlist — selected rows from Full Fundamentals

26

Pick the metrics that matter to you — click the + next to any row in Full Fundamentals above.

Your selection is saved and follows you across all tickers.

Source: SEC 10-Q filed Aug 4, 2026